IL‐10‐ and IL‐13‐Biased T Cell Responses to SARS‐CoV‐2 Vaccination in Diabetes
European Journal of Immunology · 2025
DOI: 10.1002/eji.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Emma M Jones und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Interleukin-10, SARS-CoV-2. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabetes UK, Austrian Science Fund.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 and type 2 diabetes are associated with increased severity and mortality from respiratory virus infections. Vaccination in the general population significantly reduces the risk of severe respiratory viral infection and triggers a strong, polyfunctional, and lasting T cell response in healthy individuals. However, vaccine effectiveness in people with type 1 diabetes is unclear. Here, we studied the magnitude and functional characteristics of vaccine‐specific CD4 + and CD8 + T cell responses to vaccination in people with type 1 and type 2 diabetes and compared them to those of people living without diabetes, using the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine as a model. We found defects in both CD4 + and CD8 + T cell memory maintenance and the functionality of the vaccine‐specific T cells in people with diabetes compared with people without. In those individuals with type 1 and type 2 diabetes who harbored detectable vaccine‐specific T cells, they displayed an unfocused, tolerogenic phenotype characterized by increased expression of IL‐10 and IL‐13 compared with people without diabetes. These results have implications for vaccination strategies for people with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
- Division of Cardiology, Medical University of Graz, Austria.
- Division of Rheumatology and Immunology, Medical University of Graz, Austria.
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Austria.
- University of Bayreuth, Bayreuth, Germany.
- Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Austria.
Förderung
- Diabetes UK
- Austrian Science Fund
Zitieren
APA
Jones, E. M., Sourij, C., Stradner, M., Schlenke, P., Sereban, N., Moser, O., Quinlan, R., Short, C. E., Harris, B. H. L., Fertleman, M., Taylor, G. P., Oliver, N., Sourij, H., & Dominguez-Villar, M. (2025). IL‐10‐ and IL‐13‐Biased T Cell Responses to SARS‐CoV‐2 Vaccination in Diabetes. European Journal of Immunology. https://doi.org/10.1002/eji.70112
Vancouver
Jones EM, Sourij C, Stradner M, Schlenke P, Sereban N, Moser O, et al. IL‐10‐ and IL‐13‐Biased T Cell Responses to SARS‐CoV‐2 Vaccination in Diabetes. European Journal of Immunology. 2025. doi:10.1002/eji.70112
BibTeX
@article{Jones2025,
author = {Jones, Emma M and Sourij, Caren and Stradner, Martin and Schlenke, Peter and Sereban, Nazanin and Moser, Othmar and Quinlan, Rachael and Short, Charlotte-Eve and Harris, Benjamin H L and Fertleman, Michael and Taylor, Graham P and Oliver, Nick and Sourij, Harald and Dominguez-Villar, Margarita},
title = {IL‐10‐ and IL‐13‐Biased T Cell Responses to SARS‐CoV‐2 Vaccination in Diabetes},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.70112}
}
EUVIMED